Aptose Bioscienc Stock Price, News & Analysis

Aptose Biosciences (APTO) plans to release its financial results for Q2 2020 on August 4, 2020, after market close. The results will provide insights into the company's performance and development in oncology therapeutics. The upcoming conference call is scheduled for 5 PM EDT on the same day, allowing investors to discuss the results. Aptose focuses on personalized cancer therapies addressing unmet medical needs, with investigational products like CG-806 and APTO-253 in clinical trials targeting hematological malignancies.

Aptose Biosciences has announced the pricing of a public offering of 10,500,000 common shares at US$5.25 per share, aiming to raise gross proceeds of approximately US$55 million. The offering is set to close around July 20, 2020, pending customary conditions. The funds will be utilized to enhance clinical trials for CG-806 and APTO-253, acquire new clinical assets, and support working capital. The offering is managed by Piper Sandler & Co., with additional involvement from RBC Capital Markets and others. No shares will be sold in Canada as part of this offering.

Aptose Biosciences has initiated an underwritten public offering of its common shares, with an option for underwriters to purchase an additional 15%. The proceeds will be directed toward expanding clinical trials for CG-806 and APTO-253, acquiring additional clinical assets, and general corporate purposes. The offering is contingent on market conditions and requires approval from both the Toronto Stock Exchange and Nasdaq. Piper Sandler & Co. is the sole active book-running manager for this offering.

Aptose Biosciences Inc. (Nasdaq: APTO) announced the FDA's approval of the IND application for CG-806, an oral FLT3/BTK inhibitor, allowing a Phase 1a/b study in acute myeloid leukemia (AML) patients. This follows its ongoing Phase 1 study in B-cell malignancies. The trial aims to address challenges faced by patients with relapsed or refractory AML, with the initiation planned for the second half of 2020. CG-806 showcases a promising profile with preclinical evidence of efficacy against AML and safety in animal models, offering new hope for difficult-to-treat patient populations.

Aptose Biosciences (NASDAQ: APTO) announced promising early results from a Phase 1 trial of CG-806, a novel oral FLT3/BTK inhibitor for treating chronic lymphocytic leukemia (CLL) and other B-cell cancers. The trial evaluated CG-806 safety and tolerability across three dose levels (150mg, 300mg, 450mg), reporting no serious adverse events. Significant pharmacologic activity was observed, with complete inhibition of phospho-BTK and phospho-FLT3 in treated patients. An Investigational New Drug (IND) application for further studies in acute myeloid leukemia (AML) has also been submitted.

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) held its annual meeting on June 2, 2020, where 73.21% of shareholders participated. All nominees listed in the proxy statement dated April 24, 2020, were elected as Directors. Voting outcomes showed high approval rates, with over 99% of votes cast in favor for most nominees. Additionally, shareholders re-appointed KPMG LLP as the independent registered public accounting firm. The company focuses on developing innovative cancer therapies, particularly for hematological malignancies, with two investigational drugs currently in clinical trials.

Aptose Biosciences, a clinical-stage biotechnology firm, will attend the RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020. Their presentation is scheduled from 3:40 to 4:05 pm EDT. The event will include investor meetings and a fireside chat format. Aptose focuses on developing personalized cancer therapies, notably two agents in clinical trials: CG-806, a first-in-class kinase inhibitor for hematologic malignancies, and APTO-253, targeting the MYC oncogene for acute myeloid leukemia.

Aptose Biosciences has announced an equity distribution agreement with Piper Sandler and Canaccord Genuity to offer common shares on NASDAQ. The offering allows for the sale of up to $75 million in common shares through at-the-market distributions. The TSX and NASDAQ have conditionally approved the Offering. The Company is focused on developing personalized cancer therapies, with two investigational products in clinical trials targeting hematologic malignancies. Investors are advised to review the prospectus for detailed information before considering investment.

Aptose Biosciences reported a net loss of $11.5 million for Q1 2020, up from $5.5 million in Q1 2019. Total cash and equivalents stood at $90 million. The company continues its Phase 1 trials for CG-806 and APTO-253 amid COVID-19 disruptions, with no material delays reported. CG-806 has advanced to a fourth dose level, showing promising safety and pharmacologic activity. The firm plans to submit an IND for CG-806 in AML treatment. R&D expenses rose to $5.9 million, reflecting increased program costs and stock-based compensation.